nach oben

Diabetologia

Erschienen in:

08.02.2022 | Review

One size does not fit all: an historian’s perspective on precision diabetes medicine

verfasst von: Arleen M. Tuchman

Erschienen in: Diabetologia | Ausgabe 11/2022

Einloggen, um Zugang zu erhalten

Abstract

This article offers an historical approach to exploring precision medicine’s potential for reducing health disparities in diabetes. It examines case studies from the twentieth-century USA, from early twentieth-century beliefs that Jews were most at risk of developing diabetes to claims in the 1980s that Native Americans, African Americans, Hispanic Americans and Asian Americans had the greatest likelihood of developing the disease. These case studies reveal that attempts to understand perceived health disparities have long tended to focus on the biology and behaviours of the unwell, while paying less attention to food security, workplace hazards, access to quality healthcare and other social determinants of health. The precision medicine initiative, I argue, has an opportunity to right this imbalance by leveraging the tools of big data to learn more not only about biomarkers but also about the social and physical environments in which people live and work.

Hill-Briggs F, Adler NE, Berkowitz SA et al (2020) Social determinants of health and diabetes: a scientific review. Diabetes Care 44(1):258–279 https://doi-org.proxy.library.vanderbilt.edu/10.2337/dci20-0053CrossRef

Burke W, Trinidad SB, Schenck D (2019) Can precision medicine reduce the burden of diabetes? Ethn Dis 29(Suppl 3):669–674. https://doi.org/10.18865/ed.29.S3.669CrossRefPubMedPubMedCentral

Khoury MJ, Galea S (2016) Will precision medicine improve population health? JAMA 316(13):1357–1358. https://doi.org/10.1001/jama.2016.12260CrossRefPubMedPubMedCentral

Matthew DB (2019) Two threats to precision medicine equity. Ethn Dis 29(Suppl 3):629–640. https://doi.org/10.18865/ed.29.S3.629CrossRefPubMedPubMedCentral

Konkel L (2020) Who Will Benefit from Precision Medicine? UCSF Magazine Winter: 1–19

Chung WK, Erion K, Florez JC et al (2020) Precision medicine in diabetes: a consensus report from the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care 43(7):1617–1635. https://doi.org/10.2337/dci20-0022

National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington (DC): National Academies Press (US); 2011. PMID: 22536618, Box 3–1, p 44

Burris HH, Wright CJ, Kirpalani H et al (2019) The promise and pitfalls of precision medicine to resolve black-white racial disparities in preterm birth. Pediatr Res 87(2):221–226. https://doi.org/10.1038/s41390-019-0528-zCrossRefPubMed

Parikh RB, Jain SH, Navathe AS (2019) The sociobehavioral phenotype: applying a precision medicine framework to social determinants of health. Am J Manag Care 25(9):421–423PubMed

10.

Kwon IG, Kim SH, Martin D (2021) Integrating social determinants of health to precision medicine through digital transformation: an exploratory roadmap. Int J Environ Res Public Health 18(9):5018. https://doi.org/10.3390/ijerph18095018CrossRefPubMedPubMedCentral

11.

Starr P (1982) The social transformation of American medicine. Basic Books, New York

12.

Porter R (1997) The greatest benefit to mankind. W. W. Norton & Company, New York

13.

Colgrove J (2002) The McKeown thesis: a historical controversy and its enduring influence. Am J Public Health 92(5):725–729. https://doi.org/10.2105/ajph.92.5.725CrossRefPubMedPubMedCentral

14.

Byrd W, Michael CL (2000–2002) An American Health Dilemma: Race, Medicine, and Health Care in the United States, 2 vols. New York, Routledge

15.

Hammonds EM, Reverby SM (2019) Toward a historically informed analysis of racial health disparities since 1619. Am J Public Health 109(10):1348–1349. https://doi.org/10.2105/AJPH.2019.305262CrossRefPubMedPubMedCentral

16.

Tuchman AM (2020) Diabetes: a history of race and disease. Yale University Press, New HavenCrossRef

17.

Osler W (1892) The principles and practice of medicine, 1st edn. D. Appleton, New York, p 275

18.

Joslin EP (1917) The treatment of diabetes mellitus, 1st edn. Lea & Febiger, Philadelphia, p 46

19.

Jacobs J, Fishberg M (1901–1906) Diabetes Mellitus. JewishEncyclopedia.com, https://www.jewishencyclopedia.com/articles/5161-diabetes-mellitus, accessed October 11, 2021

20.

Wilson JG (1912) Increase in the death rate from diabetes—a possible explanation. Med Rec 82:662–663

21.

Lees H (1936) Two million tightrope walkers. Collier’s May 16:34

22.

Kleen E (1900) On diabetes mellitus and glycosuria. P. Blakiston’s Son & Co, Philadelphia, pp 15–19

23.

Fitz RH, Joslin EP (1898) Diabetes mellitus at the Massachusetts General Hospital from 1824 to 1898. A study of the medical records. JAMA 31:165–171CrossRef

24.

Joslin EP (1924) The diabetic problem of today. JAMA 83:727–729. https://doi.org/10.1001/jama.1924.02660100001001CrossRef

25.

Joslin EP (1921) The prevention of diabetes mellitus. JAMA 76:79–84CrossRef

26.

Epstein AA (1919) Diabetes among Jews—its cause and prevention. Mod Med 1:269–275

27.

(1925) Adiposity and other Etiological Factors in Diabetes Mellitus. JAMA 84: 1775–76

28.

Rimoin DL (1967) Genetics of diabetes mellitus. Diabetes 16:346–351. https://doi.org/10.2337/diab.16.5.346CrossRefPubMed

29.

Rimoin DL (1969) Ethnic variability in glucose tolerance and insulin secretion. Arch Intern Med 124:695–700. https://doi.org/10.1001/archinte.1969.00300220047008CrossRefPubMed

30.

Rimoin DL, Saiki JH (1968) Diabetes mellitus among the Navajo. II. Plasma glucose and insulin responses. Arch Intern Med 122:6–9. https://doi.org/10.1001/archinte.1968.00300060008002CrossRefPubMed

31.

Miller M, Bennett PH, Burch TA (1968) Hyperglycemia in Pima Indians: A Preliminary Appraisal of Its Significance. In: Biomedical Challenges Presented by the American Indian. Washington, DC, Pan American Health Organization, 89–103

32.

Neel JV (1962) Diabetes mellitus: a ‘thrifty’ gene rendered detrimental by ‘Progress’? Am J Hum Genet 14:363–362

33.

(1980) Mike Myers—Excerpts from an Interview. Akwesasne Notes Sept;12: 23

34.

(1982) Native People, Colonialism, and Food. Akwesasne Notes Mar;13: 24–25

35.

(1974) New Hope in Health Care for Native Americans. Akwesasne Notes April;6 (April): 28

36.

Smith-Morris C (2006) Diabetes among the Pima: stories of survival. University of Arizona Press, Tucson

37.

U.S. Department of Health and Human Services. Report of the Secretary’s Task Force on Black & Minority Health (2006) (Heckler Report) Washington, DC, U.S. Government Printing Office

38.

Gamble VN, Stone D (2006) U.S. policy on health inequities: the interplay of politics and research. J Health Polit Policy Law 31:93–126. https://doi.org/10.1215/03616878-31-1-93CrossRefPubMed

39.

Gadson SL (2006) Health equality: the new civil rights frontier. J Natl Med Assoc 98(3):324–329PubMedPubMedCentral

40.

Jones EI (1976) President’s column: closing the health status gap for blacks and other minorities. J Natl Med Assoc 78:485–488

Titel: One size does not fit all: an historian’s perspective on precision diabetes medicine
verfasst von: Arleen M. Tuchman
Publikationsdatum: 08.02.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 11/2022
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-022-05660-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

22.05.2024 Obstipation Nachrichten

Bei chronischer Verstopfung wirken Kiwis offenbar besser als Flohsamenschalen. Das zeigen die Daten aus einer randomisierten Studie, die der Gastroenterologe Oliver Pech beim Praxis-Update vorstellte.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2022

Where to for precision treatment of HNF1A-MODY?

Pharmacoepigenetics in type 2 diabetes: is it clinically relevant?

The role of mental disorders in precision medicine for diabetes: a narrative review

Coordination of glucose monitoring, self-care behaviour and mental health: achieving precision monitoring in diabetes

Personalised prevention of type 2 diabetes